Drugs giant Johnson & Johnson (J&J) has been ordered by a US judge to pay $1.1bn (£690m) for downplaying the risks involved in taking its anti-psychotic drug Risperdal.
The state of Arkansas sued J&J and its subsidiary Janssen Pharmaceuticals over its marketing of the drug in 2007.
A number of US states have already found the firms guilty of similar charges and fined them accordingly.
Janssen said it was “disappointed” with the judge’s decision.
The company added that if its motion for a retrial was denied, it would appeal the fine.
“During the nearly three-week trial, Janssen presented abundant evidence showing the company acted responsibly and fully complied with all laws and regulations regarding Risperdal,” it said in a written statement.